Table 2 Distribution of metastatic sites among studied group
From: 18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer
Site | Findings | Total No. = 79 | Status | X2 | P | |
|---|---|---|---|---|---|---|
Synchronous No. = 35 | Metachronous No. = 44 | |||||
LNs mets | Positive | 47 (59.5%) | 29 (82.9%) | 18 (40.9%) | ||
Negative | 32 (40.5%) | 6 (17.1%) | 26 (59.1%) | 18.8 | 0.00** | |
LNs Site | Regional | 39 (49.4%) | 31 (88.6%) | 8 (18.2%) | 45.1 | 0.00** |
Non-regional | 16 (20.3%) | 0 (0.0%) | 16 (36.4%) | |||
Reg. and Non- reg | 8 (10.1%) | 4 (11.4%) | 4 (9.1%) | |||
Liver mets | Positive | 51 (64.6%) | 29 (82.9%) | 22 (50%) | ||
Negative | 28 (35.4%) | 6 (17.1%) | 22 (50%) | 9.3 | 0.01* | |
Peritoneal mets | Positive | 24 (30.4%) | 8 (22.9%) | 16 (36.4%) | ||
Negative | 55 (69.6%) | 27 (77.1%) | 28 (63.6%) | 8.3 | 0.016* | |
Lung mets | Positive | 25 (31.6%) | 15 (42.9%) | 10 (22.7%) | ||
Negative | 54 (68.4%) | 20 (57.1%) | 34 (77.3%) | 7.1 | 0.029* | |
Bone mets | Positive | 13 (16.5%) | 7 (20.0%) | 6 (13.6%) | ||
Negative | 66 (83.5%) | 28 (80.0%) | 38 (86.4%) | 2.1 | 0.35 | |
Spleen mets | Positive | 2 (2.5%) | 2 (5.7%) | 0 (0.0%) | ||
Negative | 77 (97.5%) | 33 (94.3%) | 44 (100.0%) | 2.6 | 0.108 | |